Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:01 PM ET 5/24/2013
Last 10 Quotes:
What's This?
| Fiscal Q1 Ending 03/13 |
Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
|
Sales/Revenue |
6,471,000 | 6,802,000 | 6,527,000 | 6,462,000 | 6,640,000 |
Cost of Goods Sold (COGS) incl. D&A |
1,981,000 | 2,011,000 | 2,081,000 | 1,806,000 | 1,815,000 |
COGS excluding D&A |
1,422,000 | 1,667,000 | 1,687,000 | 1,559,000 | 1,575,000 |
Depreciation & Amortization Expense |
559,000 | 344,000 | 394,000 | 247,000 | 240,000 |
Gross Income |
4,490,000 | 4,791,000 | 4,446,000 | 4,656,000 | 4,825,000 |
SG&A Expense |
2,812,000 | 3,339,000 | 3,158,000 | 2,836,000 | 2,930,000 |
Research & Development |
857,000 | 1,141,000 | 934,000 | 880,000 | 892,000 |
Other SG&A |
1,955,000 | 2,198,000 | 2,224,000 | 1,956,000 | 2,038,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
215,000 | NA | 199,000 | 459,000 | 166,000 |
Non Operating Income/Expense |
113,000 | 475,000 | 590,000 | 375,000 | 308,000 |
Interest Expense |
199,000 | 186,000 | 197,000 | 191,000 | 234,000 |
Gross Interest Expense |
199,000 | 186,000 | 197,000 | 191,000 | 234,000 |
Pretax Income |
1,400,000 | 1,741,000 | 1,501,000 | 1,552,000 | 1,869,000 |
Income Tax |
382,000 | 912,000 | 314,000 | 233,000 | 489,000 |
Equity in Affiliates |
11,000 | 10,000 | 9,000 | 0 | 10,000 |
Consolidated Net Income |
1,029,000 | 839,000 | 1,196,000 | 1,319,000 | 1,390,000 |
Minority Interest Expense |
68,000 | -25,000 | 74,000 | 65,000 | 65,000 |
Net Income |
961,000 | 864,000 | 1,122,000 | 1,254,000 | 1,325,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | NA | 0 | NA | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
961,000 | 864,000 | 1,122,000 | 1,254,000 | 1,324,999 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
961,000 | 864,000 | 1,122,000 | 1,254,000 | 1,325,000 |
Operational EPS |
0.23 | 0.17 | 0.25 | 0.32 | 0.29 |
EPS (basic) |
0.20 | 0.18 | 0.23 | 0.25 | 0.27 |
EBITDA |
2,237,000 | 1,796,000 | 1,682,000 | 2,067,000 | 2,135,000 |
Depreciation & Amortization Expense |
559,000 | 344,000 | 394,000 | 247,000 | 240,000 |
Common Shares Outstanding |
4,834,000 | 4,912,000 | 4,897,000 | 4,945,000 | 4,963,000 |
Basic Shares Outstanding |
4,834,000 | 4,912,000 | 4,897,000 | 4,945,000 | 4,963,000 |
Diluted Shares Outstanding |
4,847,000 | 4,989,000 | 4,972,000 | 4,996,000 | 5,035,000 |
Diluted EPS after Extraordinary Items |
0.20 | 0.17 | 0.23 | 0.25 | 0.26 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.20 | 0.18 | 0.23 | 0.25 | 0.27 |
*Figures in thousands of U.S. Dollars except shares outstanding.
